Clin Mol Hepatol.
2024 Oct;30(4):1019-1022. 10.3350/cmh.2024.0471.
The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid’s mechanisms of action: Correspondence to editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease”
- Affiliations
-
- 1Department of Gastroenterology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
- 2Department of Spleen, Stomach and Hepatobiliary, Zhongshan Hospital of Traditional Chinese Medicine, Zhongshan, China
- 3Department of Hepatobiliary Diseases, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, State Key Laboratory of Traditional Chinese Medicine Syndrome, Guangzhou, China
- 4Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou, China
- 5Department of Gastroenterology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
- 6Department of Gastroenterology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China
- 7The First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, China
- 8Medical Affairs Department, Ton-Bridge Medical Technology Co., Ltd., Zhuhai, China
- KMID: 2560114
- DOI: http://doi.org/10.3350/cmh.2024.0471
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Ursolic acid: A promising therapeutic agent for metabolic dysfunction-associated steatotic liver disease via inhibition of SPP1-induced Th17 cell differentiation: Editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease”
- Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease
- Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences
- Sex differences in metabolic dysfunction-associated steatotic liver disease: a narrative review
